<DOC>
	<DOCNO>NCT01126541</DOCNO>
	<brief_summary>This study compare efficacy safety re-treatment 2 dos MabThera ( rituximab ) patient active rheumatoid arthritis ( RA ) previously experience inadequate response intolerance anti-tumor necrosis factor ( anti-TNF ) therapy etanercept , infliximab adalimumab therapy . All patient receive infusion 1000 mg intravenous ( IV ) MabThera Days 1 15 ; Week 24 patient demonstrated moderate good response randomize receive re-treatment either 1 2 additional infusion 1000 mg IV MabThera . The anticipated time study treatment 2+ year , target sample size 100-500 individual .</brief_summary>
	<brief_title>SMART Study : A Study Re-treatment With MabThera ( Rituximab ) Patients With Rheumatoid Arthritis Who Have Failed Anti-TNF Alfa Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Adult patient &gt; 18 year age RA &gt; =6 month Receiving outpatient treatment Ongoing treatment methotrexate &gt; =3 month , stable &gt; =1 month Inadequate response intolerance etanercept , infliximab adalimumab Previous treatment MabThera Concurrent treatment anti TNFalfa therapy biologic therapy Previous treatment investigational celldepleting therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>